The Impact of Magnesium on Exercise Tolerance, Quality of Life and Clinical Outcomes in Chronic Heart Failure Patients

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Magnesium supplementation could improve cardiac performance. Patients with chronic heart failure (CHF) are magnesium deficient and we hypothesized that 1 year supplementation of oral magnesium comparted to placebo will improve exercise duration time and quality of life.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sheba Medical Center
• Collaborator: Naveh Pharma (1996) Ltd.
• Treatments: Magnesium Oxide

Criteria

Inclusion Criteria:

• CHF patients NYHA II-IV > 3 months

• Diuretic therapy > 3 months

• Signed informed consent

Exclusion Criteria:

• chronic renal failure (serum creatinine > 3 mg/dL)

• AMI/ACS< 3 months from randomization

• Cardiac or other organ transplantation

• Uncontrolled hypo/hyperthyroidism

• Chronic diarrhea

• Life expectancy < 1 year

• Known psychiatric disease which inhibits patient's enrollment to the study

• Inability to come for follow-up visits

• Any planned operation/invasive procedures in the near 6 months

• Uncontrolled cardiac arrhythmias

• Inability to perform 6 minute walk testing

• Any participation in another interventional clinical trial < 1 month from randomization

• Any malignancy with life expectancy < 1 year Any AV Block> 2 degree without a pacemaker